Business Context and Reporting Period
This Form 8-K filing by Pavmed Inc. (PAVM) reports on the results of the Annual Meeting of Stockholders held on June 18, 2025. The company is incorporated in Delaware and trades on The Nasdaq Stock Market LLC.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance and stockholder voting outcomes.
Material Changes and Voting Results
Stockholders representing approximately 77.2% of outstanding shares participated in the meeting. The following matters were approved:
- Director Elections: Lishan Aklog, M.D., and Michael J. Glennon were re-elected as Class C directors. Significant broker non-votes (5,323,902 shares) were recorded for these elections.
- Stock Issuance Approval: Stockholders approved the issuance of common stock upon exercise of pre-funded warrants sold in a February 2025 private placement, satisfying Nasdaq Listing Rule 5635.
- Equity Plan Amendment: The 2014 Long-Term Incentive Equity Plan was amended to increase the share reserve by 2,500,000 shares, raising the total available shares from 2,412,140 to 4,912,140.
- Executive Compensation: The advisory vote on executive compensation was approved.
- Auditor Ratification: Marcum LLP was ratified as the independent registered public accounting firm for the year ending December 31, 2025.
Guidance, Outlook, and Risks
The filing does not contain management commentary on future financial guidance, operational outlook, or specific risk factors. It references a Definitive Proxy Statement filed on April 30, 2025, for detailed descriptions of the pre-funded warrants and the equity plan amendment.
Investor Verification Checklist
- Verify the terms of the pre-funded warrants issued in the February 2025 private placement referenced in the Definitive Proxy Statement.
- Review the full text of the Sixth Amended and Restated 2014 Long-Term Incentive Equity Plan (Exhibit 10.1) to understand vesting schedules and dilution implications.
- Confirm the impact of the 2,500,000 share increase on the 2014 Plan on future employee compensation costs.
- Check the May 15, 2025 Form 10-Q for the most recent financial position and liquidity status, as this 8-K does not contain financial data.